Fig. 8
Nondiabetic plasma-treated SVFs increase Akt activation and attenuate glucose intolerance in Leprdb/db mice. A Leprdb/db SVFs were treated with plasma from Lepr+/+ mice. Increased numbers (1 × 107 and 2 × 107) of Lepr+/+ plasma-treated SVFs were injected into the inguinal WAT of Leprdb/db mice. Lepr+/+ and Leprdb/db mice treated with PBS were served as controls. One week after injection, mice were treated with vehicle or insulin 1.25 mIU/g body weight for 20 min. Mice were then killed and SVFs were harvested followed by western blot analysis for pAkt, Akt, pERK, and ERK expression. B The ratios of pAkt/Akt and pERK/ERK were calculated. C After 15 h fasting, Lepr+/+ mice treated with PBS, Leprdb/db mice treated with PBS, and Leprdb/db mice injected with Lepr+/+ plasma-treated SVFs were administered with glucose. The blood glucose level was measured before and every 15 min up to 2 h after glucose administration by using a glucose meter. N = 4/group. *p < 0.05; **p < 0.01; ***p < 0.001 compared to Lepr+/+ mice. #p < 0.05; ##p < 0.01 compared to Leprdb/db mice